Endo International plc’s subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc. for the development, registration, supply, commercialization and distribution of QRX003 on an exclusive basis in Canada. If the product is approved, Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities in Canada.   QRX003 is Quoin’s lead product for Netherton syndrome. A form of ichthyosis, Netherton syndrome is a rare heredit...